PLoS ONE (Jan 2022)

Chromogranin A plasma levels predict mortality in COVID-19

  • Rebecca De Lorenzo,
  • Clara Sciorati,
  • Giuseppe A. Ramirez,
  • Barbara Colombo,
  • Nicola I. Lorè,
  • Annalisa Capobianco,
  • Cristina Tresoldi,
  • Bio Angels for COVID-BioB Study Group,
  • Daniela M. Cirillo,
  • Fabio Ciceri,
  • Angelo Corti,
  • Patrizia Rovere-Querini,
  • Angelo A. Manfredi

Journal volume & issue
Vol. 17, no. 4

Abstract

Read online

Background Chromogranin A (CgA) and its fragment vasostatin I (VS-I) are secreted in the blood by endocrine/neuroendocrine cells and regulate stress responses. Their involvement in Coronavirus 2019 disease (COVID-19) has not been investigated. Methods CgA and VS-I plasma concentrations were measured at hospital admission from March to May 2020 in 190 patients. 40 age- and sex-matched healthy volunteers served as controls. CgA and VS-I levels relationship with demographics, comorbidities and disease severity was assessed through Mann Whitney U test or Spearman correlation test. Cox regression analysis and Kaplan Meier survival curves were performed to investigate the impact of the CgA and VS-I levels on in-hospital mortality. Results Median CgA and VS-I levels were higher in patients than in healthy controls (CgA: 0.558 nM [interquartile range, IQR 0.358–1.046] vs 0.368 nM [IQR 0.288–0.490] respectively, p = 0.0017; VS-I: 0.357 nM [IQR 0.196–0.465] vs 0.144 nM [0.144–0.156] respectively, pConclusion Plasma CgA levels increase in COVID-19 patients and represent an early independent predictor of mortality.